These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 15936733)

  • 1. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease.
    Saravanan KS; Sindhu KM; Mohanakumar KP
    Brain Res; 2005 Jul; 1049(2):147-55. PubMed ID: 15936733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
    Saravanan KS; Sindhu KM; Senthilkumar KS; Mohanakumar KP
    Neurochem Int; 2006 Jul; 49(1):28-40. PubMed ID: 16490285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion.
    Sindhu KM; Saravanan KS; Mohanakumar KP
    Brain Res; 2005 Jul; 1051(1-2):25-34. PubMed ID: 15992782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rotenone increases glutamate-induced dopamine release but does not affect hydroxyl-free radical formation in rat striatum.
    Leng A; Feldon J; Ferger B
    Synapse; 2003 Dec; 50(3):240-50. PubMed ID: 14515342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine.
    Sindhu KM; Banerjee R; Senthilkumar KS; Saravanan KS; Raju BC; Rao JM; Mohanakumar KP
    Pharmacol Biochem Behav; 2006 Jun; 84(2):321-9. PubMed ID: 16820197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle.
    Norazit A; Meedeniya AC; Nguyen MN; Mackay-Sim A
    Brain Res; 2010 Nov; 1360():119-29. PubMed ID: 20807515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures.
    Testa CM; Sherer TB; Greenamyre JT
    Brain Res Mol Brain Res; 2005 Mar; 134(1):109-18. PubMed ID: 15790535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers.
    Sengstock GJ; Olanow CW; Menzies RA; Dunn AJ; Arendash GW
    J Neurosci Res; 1993 May; 35(1):67-82. PubMed ID: 7685399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive changes in striatal dopaminergic markers, nigral volume, and rotational behavior following iron infusion into the rat substantia nigra.
    Sengstock GJ; Olanow CW; Dunn AJ; Barone S; Arendash GW
    Exp Neurol; 1994 Nov; 130(1):82-94. PubMed ID: 7529713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute intranigral homocysteine administration produces stereotypic behavioral changes and striatal dopamine depletion in Sprague-Dawley rats.
    Chandra G; Gangopadhyay PK; Senthil Kumar KS; Mohanakumar KP
    Brain Res; 2006 Feb; 1075(1):81-92. PubMed ID: 16487496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease.
    Caboni P; Sherer TB; Zhang N; Taylor G; Na HM; Greenamyre JT; Casida JE
    Chem Res Toxicol; 2004 Nov; 17(11):1540-8. PubMed ID: 15540952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone.
    Fleming SM; Zhu C; Fernagut PO; Mehta A; DiCarlo CD; Seaman RL; Chesselet MF
    Exp Neurol; 2004 Jun; 187(2):418-29. PubMed ID: 15144868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
    Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
    Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium salicylate protects against rotenone-induced parkinsonism in rats.
    Madathil SK; Karuppagounder SS; Mohanakumar KP
    Synapse; 2013 Aug; 67(8):502-14. PubMed ID: 23447126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease.
    Verma R; Nehru B
    Neurochem Int; 2009 Nov; 55(6):369-75. PubMed ID: 19375462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model.
    Blandini F; Levandis G; Bazzini E; Nappi G; Armentero MT
    Eur J Neurosci; 2007 Jan; 25(2):397-405. PubMed ID: 17284180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-synuclein and tyrosine hydroxylase expression in acute rotenone toxicity.
    Luo C; Rajput AH; Akhtar S; Rajput A
    Int J Mol Med; 2007 Mar; 19(3):517-21. PubMed ID: 17273802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model.
    Saravanan KS; Sindhu KM; Mohanakumar KP
    J Pineal Res; 2007 Apr; 42(3):247-53. PubMed ID: 17349022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats.
    Alam M; Schmidt WJ
    Behav Brain Res; 2004 Aug; 153(2):439-46. PubMed ID: 15265640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.